Skip to contentpdufa.bio

Elsunersen EMBRAVE3 (registrational)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Elsunersen EMBRAVE3 (registrational) is a Praxis Precision Medicines Inc. program in early-seizure-onset SCN2A DEE. Its next catalyst is a Readout in Q4 2027.

PRAX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Early-seizure-onset SCN2A DEE. Sponsor: Praxis Precision Medicines Inc. (PRAX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027PRAX

Specialist biotech funds holding PRAX, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Perceptive Advisors2,024,781$589.7 millionfiled November 16, 2026
Baker Bros. Advisors1,753,198$510.6 millionfiled November 16, 2026
Cormorant Asset Management500,000$145.6 millionfiled November 16, 2026
OrbiMed Advisors200,400$58.4 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Elsunersen EMBRAVE3 (registrational)'s next FDA decision or readout?

The next tracked catalyst for Elsunersen EMBRAVE3 (registrational) is a Readout in Q4 2027.

What happened at Elsunersen EMBRAVE3 (registrational)'s most recent FDA decision?

No FDA decision for Elsunersen EMBRAVE3 (registrational) is in our archive yet.

What is Elsunersen EMBRAVE3 (registrational) used for?

In our records Elsunersen EMBRAVE3 (registrational) is under review or in development for Early-seizure-onset SCN2A DEE.

Who makes Elsunersen EMBRAVE3 (registrational)?

Praxis Precision Medicines Inc. (PRAX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.